Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

Huanyu Zhou,Li Xi,Daniel Ziemek,Shawn P. O'Neil,Julie Lee,Zachary S. Stewart,Yutian Zhan,Shanrong Zhao,Ying Zhang,Karen Page,Austin Huang,Mateusz Maciejewski,Baohong Zhang,Kenneth J. Gorelick,Lori Fitz,Vivek Pradhan,Fabio Cataldi,Michael S. Vincent,David von Schack,Kenneth E. Hung,Mina Hassan-Zahraee

Molecular Profiling of Ulcerative Colitis Subjects from the TURANDOT Trial Reveals Novel Pharmacodynamic/Efficacy Biomarkers

2019

Background and Aims To define pharmacodynamic and efficacy biomarkers in ulcerative colitis [UC] patients treated with PF-00547659, an anti-human mucosal addressin cell adhesion molecule-1 [MAdCAM-1] monoclonal antibody, in the TURANDOT study.

Keywords:

Pharmacodynamics
Physical therapy
Diabetes mellitus
Ulcerative colitis
Oncology
Biomarker (medicine)
Medicine
Internal medicine
Immunology
Vedolizumab
Biopsy
CCR9
Inflammatory bowel disease
Transcriptome
Addressin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations